The Impact of Flavonoid Supplementation on Serum Oxidative Stress Levels Measured via D-ROMs Test in the General Population: The PREVES-FLAVON Retrospective Observational Study.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
29 Sep 2024
Historique:
received: 28 08 2024
revised: 25 09 2024
accepted: 26 09 2024
medline: 16 10 2024
pubmed: 16 10 2024
entrez: 16 10 2024
Statut: epublish

Résumé

Oxidative stress has emerged as a key contributor to numerous NCDs (non-communicable diseases), including cardiovascular diseases, cancer, and diabetes. This study aims to explore the potential of targeted interventions to mitigate oxidative stress as part of a primary prevention strategy. The study included 32 healthy participants (11 men, 21 women) aged 45-65 who completed both the initial and follow-up assessments of the Healthy Days Initiative, a community-based wellness program organized by the non-profit Associazione O.R.A. ETS. Through blood analysis, vital sign assessment, lifestyle questionnaires, and individualized recommendations, participants received guidance on improving their health and reducing disease risk. The initiative also offered the opportunity for participants to consume a flavonoid supplement containing quercitrin, rutin, and hesperidin, with the goal of reducing oxidative stress. Participants who opted for supplementation were instructed to take 1-2 tablets daily for two weeks. Data collected included demographic information, anthropometric measurements, vital signs, dietary and lifestyle habits, medical history, WHO-5 Well-Being Index scores, and blood parameters. Significant reductions were observed in glucose levels (from 82 to 74.5 mg/dL), reactive oxygen metabolites (d-ROMs) (from 394.5 to 365.5 U.CARR), and systolic blood pressure (from 133 to 122 mmHg) after the two-week flavonoid intervention. Most participants (26/31) reported no side effects, and the majority (30/31) expressed a willingness to continue using a product combination of quercitrin, rutin, and hesperidin or a similar product long-term. While limited in scope and duration, the PREVES-FLAVON study contributes valuable insights to the growing body of evidence suggesting that flavonoid supplementation may play a significant role in reducing risk factors associated with NCDs in primary prevention settings. By targeting novel risk factors such as oxidative stress, this intervention holds promise for mitigating the global burden of NCDs and promoting healthy aging.

Sections du résumé

BACKGROUND BACKGROUND
Oxidative stress has emerged as a key contributor to numerous NCDs (non-communicable diseases), including cardiovascular diseases, cancer, and diabetes. This study aims to explore the potential of targeted interventions to mitigate oxidative stress as part of a primary prevention strategy.
METHODS METHODS
The study included 32 healthy participants (11 men, 21 women) aged 45-65 who completed both the initial and follow-up assessments of the Healthy Days Initiative, a community-based wellness program organized by the non-profit Associazione O.R.A. ETS. Through blood analysis, vital sign assessment, lifestyle questionnaires, and individualized recommendations, participants received guidance on improving their health and reducing disease risk. The initiative also offered the opportunity for participants to consume a flavonoid supplement containing quercitrin, rutin, and hesperidin, with the goal of reducing oxidative stress. Participants who opted for supplementation were instructed to take 1-2 tablets daily for two weeks. Data collected included demographic information, anthropometric measurements, vital signs, dietary and lifestyle habits, medical history, WHO-5 Well-Being Index scores, and blood parameters.
RESULTS RESULTS
Significant reductions were observed in glucose levels (from 82 to 74.5 mg/dL), reactive oxygen metabolites (d-ROMs) (from 394.5 to 365.5 U.CARR), and systolic blood pressure (from 133 to 122 mmHg) after the two-week flavonoid intervention. Most participants (26/31) reported no side effects, and the majority (30/31) expressed a willingness to continue using a product combination of quercitrin, rutin, and hesperidin or a similar product long-term.
CONCLUSIONS CONCLUSIONS
While limited in scope and duration, the PREVES-FLAVON study contributes valuable insights to the growing body of evidence suggesting that flavonoid supplementation may play a significant role in reducing risk factors associated with NCDs in primary prevention settings. By targeting novel risk factors such as oxidative stress, this intervention holds promise for mitigating the global burden of NCDs and promoting healthy aging.

Identifiants

pubmed: 39408268
pii: nu16193302
doi: 10.3390/nu16193302
pii:
doi:

Substances chimiques

Flavonoids 0
Reactive Oxygen Species 0
Blood Glucose 0
Rutin 5G06TVY3R7
Quercetin 9IKM0I5T1E
Hesperidin E750O06Y6O
Antioxidants 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Giuseppe Di Lorenzo (G)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.
Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.
UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.

Antonio Verde (A)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.
Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.

Luca Scafuri (L)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.
Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.

Ferdinando Costabile (F)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Vincenza Caputo (V)

Oncology Unit, "Luigi Curto" Hospital, ASL Salerno, 84035 Polla, Italy.

Rossella Di Trolio (R)

Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, 80131 Naples, Italy.

Oriana Strianese (O)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Vittorino Montanaro (V)

Urology Department, "San Leonardo" Hospital-ASL Napoli 3 Sud., Castellammare di Stabia, 80053 Naples, Italy.

Felice Crocetto (F)

Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80133 Naples, Italy.

Francesco Del Giudice (F)

Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, 00161 Rome, Italy.

Raffaele Baio (R)

Department of Urology, Umberto I, Nocera Inferiore, 84014 Salerno, Italy.

Antonio Tufano (A)

Unit of Urology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy.

Paolo Verze (P)

Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.

Alessia Nunzia Calabrese (AN)

Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy.

Carlo Buonerba (C)

Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH